https://hippo-inhibitors.com/a....pical-pelvic-organ-p
In hormone therapy-resistant acquired cell lines and patient-derived xenografts (PDX), RMC-6272 demonstrated sustained efficacy. Increased efficacy was observed in CDK4/6 inhibitor-resistant acquired cell lines treated with RMC-6272, compared to their original cell lines. RMC-6272 proved effective in a patient-derived xenograft (PDX) from a patient with resistance to CDK4/6 inhibition. Bi-
Like
Comment
Share
